



Panacea Biotec
Innovation in support of life

24th October, 2017

The Manager, Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Fax No.:022-26598237 / 38
NSE Symbol: PANACEABIO

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Fax No.:022-22721919, 3121
BSE Scrip Code: 531349

Re.: Press Release - Panacea Biotec announces launch of Prasugrel tablets (its first-to-file ANDA) in US Market

Dear Sir,

The Company is pleased to announce that its first-to-file ANDA of Prasugrel 5mg and 10mg tablets has been approved by the United States Food & Drug Administration (U.S.FDA). Under the provisions of Hatch-Waxman Act, the Company is entitled for 180-days of shared marketing exclusivity for Prasugrel HCL tablets with this final FDA approval.

The product has been launched in the market by Apotex Corp., the largest Canadian-owned pharmaceutical company which is the exclusive sales and distribution partner for this product in USA.

A copy of the Press Release titled "Panacea Biotec announces launch of Prasugrel tablets (its first-to-file ANDA) in US Market" being issued to the media, etc. in this regard is enclosed for your kind reference and record please.

Kindly acknowledge the receipt.

Thanking you,
Sincerely yours,
for **Panacea Biotec Ltd.**

Vinod Goel
Group CFO and Head Legal & Company Secretary

Encl. : As above.

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoe@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com